Brain pharmacokinetics of neurotoxin-loaded PLA nanoparticles modified with chitosan after intranasal administration in awake rats

Drug Development and Industrial Pharmacy

Volumn 39, Issue 11, 2013, Pages 1618-1624

  Zhang, Xingguo ^a,b   Liu, Lin ^b   Chai, Guobao ^a   Zhang, Xiangyi ^b   Li, Fanzhu ^a  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chitosan; Intranasal administration; Microdialysis; Neurotoxin; Pharmacokinetics; PLA nanoparticles

Indexed keywords

CHITOSAN; CHOLINERGIC RECEPTOR; FLUORESCEIN ISOTHIOCYANATE; NANOPARTICLE; NEUROTOXIN; POLYLACTIC ACID;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG TRANSPORT; ENCAPSULATION; FEMALE; FLUORESCENCE; HYDROPHILICITY; MICRODIALYSIS; NEUROTRANSMISSION; NONHUMAN; PARTICLE SIZE; PERIAQUEDUCTAL GRAY MATTER; RAT; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ADMINISTRATION, INTRANASAL; ANALGESICS, NON-NARCOTIC; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; CHITOSAN; COBRA NEUROTOXIN PROTEINS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; FLUORESCENT DYES; HALF-LIFE; LACTIC ACID; MALE; MICRODIALYSIS; NANOPARTICLES; NEURONS; PERIAQUEDUCTAL GRAY; POLYMERS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 84885666048     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.727828     Document Type: Article

References (40)

1. Bickel U, Yoshikawa T, Pardridge WM. (2001). Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev, 46:247-279
2. Banks WA. (2008). Delivery of peptides to the brain: Emphasis on therapeutic development. Biopolymers, 90:589-594
3. Frey WH II. (2002). Bypassing the blood-brain barrier to delivery therapeutic agents to the brain and spinal cord. Drug Del Tech, 2:46-49
4. Dhuria SV, Hanson LR, Frey WH 2nd. (2010). Intranasal delivery to the central nervous system: Mechanisms and experimental considerations. J Pharm Sci, 99:1654-1673
5. Wu H, Hu K, Jiang X. (2008). From nose to brain: Understanding transport capacity and transport rate of drugs. Expert Opin Drug Deliv, 5:1159-1168
6. Ali J, Ali M, Baboota S, Sahani JK, Ramassamy C, Dao L et al. (2010). Potential of nanoparticulate drug delivery systems by intranasal administration. Curr Pharm Des, 16:1644-1653
7. Vaka SR, Sammeta SM, Day LB, Murthy SN. (2009). Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake. J Pharm Sci, 98:3640-3646
8. Illum L. (2000). Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci, 11:1-18
9. Dufes C, Olivier JC, Gaillard F, Gaillard A, Couet W, Muller JM.(2003). Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm, 255:87-97
10. Krauland AH, Bernkop-Schnürch A. (2004). Thiomers: Development and in vitro evaluation of a peroral microparticulate peptide delivery system. Eur J Pharm Biopharm, 57:181-187
11. Mistrya A, Stolnika S, Illum L. (2009). NPs for direct nose-to-brain delivery of drugs. Int J Pharm, 379:146-157
12. Kumar MNVR. (2000). A review of chitin and chitosan applications. React Funct Polym, 46:1-27
13. Khor E, Lim LY. (2003). Implantable applications of chitin and chitosan. Biomaterials, 24:2339-2349
14. Llabot JM, Salman H, Millotti G, Bernkop-Schnürch A, Allemandi D, Manuel Irache J. (2011). Bioadhesive properties of poly(anhydride) nanoparticles coated with different molecular weights chitosan. J Microencapsul, 28:455-463
15. Mangal S, Pawar D, Garg NK, Jain AK, Vyas SP, Rao DS et al. (2011). Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally. Vaccine, 29:4953-4962
16. Luckachan GE, Pillai CKS. (2006). Chitosan/oligo L-lactide graft copolymers: Effect of hydrophobic side chains on the physicochemical properties and biodegradability. Carbohydrate Polymers, 64:254-266
17. Yuan XB, Li H, Yuan YB. (2006). Preparation of cholesterolmodified chitosan self-aggregated nanoparticles for delivery of drugs to ocular surface. Carbohydrate Polymers, 65:337-345
18. Sheng Y, Liu C, Yuan Y, Tao X, Yang F, Shan X, et al. (2009). Longcirculating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan. Biomaterials, 30:2340-2348
19. Tsetlin V. (1999). Snake venom alpha-neurotoxins and other three-finger proteins. Eur J Biochem, 264:281-286
20. Chung YI, Tae G, Hong Yuk S. (2006). A facile method to prepare heparin-functionalized nanoparticles for controlled release of growth factors. Biomaterials, 27:2621-2626
21. Vila A, Sánchez A, Tobío M, Calvo P, Alonso MJ. (2002). Design of biodegradable particles for protein delivery. J Control Release, 78:15-24
22. Bergquist J, Vona MJ, Stiller CO, OConnor WT, Falkenberg T, Ekman R. (1996). Capillary electrophoresis with laser-induced fluorescence detection: A sensitive method for monitoring extracellular concentrations of amino acids in the periaqueductal grey matter. J Neurosci Methods, 65:33-42
23. Paxinos G, Watson C. (1997). The Rat Brain in Stereotaxic Coordinates. Sydney: Academic Press
24. Bagger MA, Bechgaard E. (2004). The potential of nasal application for delivery to the central brain-a microdialysis study of fluorescein in rats. Eur J Pharm Sci, 21:235-242
25. Williams FG, Mullet MA, Beitz AJ. (1995). Basal release of Metenkephalin and neurotensin in the ventrolateral periaqueductal gray matter of the rat: A microdialysis study of antinociceptive circuits. Brain Res, 690:207-216
26. Trapani A, De Giglio E, Cafagna D, Denora N, Agrimi G, Cassano T et al. (2011). Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. Int J Pharm, 419:296-307
27. Tahara K, Miyazaki Y, Kawashima Y, Kreuter J, Yamamoto H. (2011). Brain targeting with surface-modified poly(D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. Eur J Pharm Biopharm, 77:84-88
28. Wang ZH, Wang ZY, Sun CS, Wang CY, Jiang TY, Wang SL. (2010). Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials, 31:908-915
29. Wang X, Chi N, Tang X. (2008). Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm, 70:735-740
30. Hoekman JD, Ho RJ. (2011). Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution. AAPS PharmSciTech, 12:534-543
31. Charlton ST, Whetstone J, Fayinka ST, Read KD, Illum L, Davis SS. (2008). Evaluation of direct transport pathways of glycine receptor antagonists and an angiotensin antagonist from the nasal cavity to the central nervous system in the rat model. Pharm Res, 25:1531-1543
32. Al-Ghananeem AM, Saeed H, Florence R, Yokel RA, Malkawi AH.(2010). Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses. J Drug Target, 18:381-388
33. Li F, Feng J, Cheng Q, Zhu W, Jin Y. (2007). Delivery of 125I-cobrotoxin after intranasal administration to the brain: A microdialysis study in freely moving rats. Int J Pharm, 328:161-167
34. Illum L. (2003). Nasal drug delivery-possibilities, problems and solutions. J Control Release, 87:187-198
35. Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev, 47:65-81
36. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B et al. (2003). Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res, 20:409-416
37. Kreuter J. (2002). Transport of drugs across the blood-brain barrier by NPs. Curr Med Chem CNS Agents, 9:241-249
38. Pan YF, Feng J, Cheng QY, Li FZ. (2007). Intracerebral microdialysis technique and its application on brain pharmacokineticpharmacodynamic study. Arch Pharm Res, 30:1635-1645
39. Hammarlund-Udenaes M. (2000). The use of microdialysis in CNS drug delivery studies. Pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv Drug Deliv Rev, 45:283-294
40. Hammarlund-Udenaes M (2010). Active-site concentrations of chemicals - Are they a better predictor of effect than plasma/organ/ tissue concentrations? Basic Clin Pharmacol Toxicol, 106:215-220